What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially announce and provide access to Gilead Sciences' financial results for the quarter ended March 31, 2022, through the inclusion of a press release as an exhibit.

Where can I find the detailed financial results for Q1 2022?

The detailed financial results are contained within the press release filed as Exhibit 99.1 to this 8-K. You should refer to this press release for specific figures and commentary.

What is the difference between GAAP and non-GAAP financial information presented by Gilead?

GAAP (Generally Accepted Accounting Principles) are standard accounting rules. Non-GAAP measures are adjusted figures that management believes provide useful insights into the company's operational performance. However, non-GAAP measures are not prepared under comprehensive accounting rules and may be calculated differently by other companies, so they should be used to supplement, not replace, GAAP information.

What are the implications of the information being 'furnished' rather than 'filed'?

Information that is 'furnished' under Item 2.02 is not subject to the liability provisions of Section 18 of the Securities Exchange Act of 1934, which typically holds companies liable for misstatements or omissions in 'filed' documents. This means the legal standard for accuracy and completeness under Section 18 does not apply to the content of this press release.

GILD 8-K: Earnings & Results

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on April 28, 2022, to announce its first-quarter 2022 financial results, as detailed in a press release issued on the same date. The filing primarily serves to furnish the press release, which contains both GAAP and non-GAAP financial measures. Investors should note that while non-GAAP measures are provided for supplemental understanding and internal management purposes, they are not prepared under comprehensive accounting rules and may differ from how other companies present similar metrics. A full reconciliation between GAAP and non-GAAP figures is available within the press release. The press release itself, Exhibit 99.1, is the core of this filing and provides the detailed financial performance for the quarter ended March 31, 2022. Investors seeking to understand Gilead's operational and financial condition for the period should refer to this exhibit. The company emphasizes that information furnished under Item 2.02 and Item 9.01, including Exhibit 99.1, is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same legal implications as formally filed information regarding accuracy and completeness under that specific section.

Key Highlights

1Gilead Sciences announced its Q1 2022 financial results via an 8-K filing on April 28, 2022.
2The primary information source is a press release (Exhibit 99.1) detailing financial results for the quarter ended March 31, 2022.
3The company presented financial information using both U.S. GAAP and non-GAAP measures.
4Non-GAAP financial information is provided as a supplement to GAAP results and for internal management insights.
5Investors are advised to use non-GAAP measures cautiously, as they are not prepared under comprehensive accounting rules and definitions may vary across companies.
6A reconciliation of GAAP to non-GAAP financial measures is available in the press release (pages 10-12).
7Information in this 8-K is furnished, not filed under Section 18 of the Exchange Act, meaning it has different legal implications regarding liability.

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Apr 28, 2022)

Summary

Key Highlights

Frequently Asked Questions